MLN2238 exerts its anti-tumor effects <i>via</i> regulating ROS/JNK/mitochondrial signaling pathways in intrahepatic cholangiocarcinoma.

Front Pharmacol · 2022 · PMC9659592 · PMID 36386204

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

After MLN2238 treatment for 24 h, the percentages of HuCCT-1 and CCLP-1 in the G2/M phase were significantly increased, whereas the cell population in the G0/G1 phase showed a decreasing trend ( Figures 4D,E ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.